IL-2 mutein selectively expands thymic memory Tregs with increased transendocytosis in healthy participants.
Laura A Cooney, Mitch Fahning, Liliane Khoryati et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, single-ascending-dose trial in healthy human participants examined how the IL-2 mutein MK-6194 affects regulatory T-cell (Treg) subsets and function. After a single subcutaneous dose, thymus-derived Tregs were selectively activated and expanded, whereas peripherally induced Tregs were unaffected. The expanded cells showed gene and protein changes consistent with activation, suppressor function, and nonlymphoid-tissue homing, alongside increased CTLA-4-dependent capture of CD80 and CD86 from non-Tregs. The findings characterize cellular effects that may help explain how Treg-targeted therapy could promote immune tolerance.
Key findings
- A single subcutaneous dose selectively activated and expanded thymus-derived Tregs; peripherally induced Tregs were unaffected.
- Expanded Tregs showed increased expression of genes and proteins consistent with activation, suppressor function, and homing to nonlymphoid tissue.
- Expanded Tregs had increased transendocytosis, measured by CTLA-4-dependent capture of CD80 and CD86 from non-Tregs.
Why it matters
Treg-promoting therapies are being developed for inflammatory disorders, but their effects on Treg subsets and function are not fully understood. These results indicate that MK-6194’s effects in healthy participants were selective rather than uniform across Treg populations, and included functional changes relevant to immune suppression. This cellular characterization may inform understanding of how such therapies could support immune tolerance.
What to keep in mind
The human findings followed a single dose in healthy participants; the abstract does not report clinical outcomes in people with inflammatory disorders.